Clinicopathological data of paired diagnosis and recurrence cHL cohort at the time of primary diagnosis
Total cohort (N = 60) . | n (%) . |
---|---|
Sex (N = 60) | |
Male | 37 (62) |
Female | 23 (38) |
Median age (N = 60) | 26 y (4-76 y) |
Pediatric (≤18 y) | 18 (30) |
Adults (>18 y) | 42 (70) |
Disease stage Ann Arbor (n = 52) | |
I | 6 (12) |
II | 19 (37) |
III | 17 (33) |
IV | 10 (19) |
Risk groups (n = 40) | |
Stages I to II (n = 24) | |
EORTC favorable | 9 (23) |
EORTC unfavorable | 15 (38) |
Stages III to IV (n = 16) | |
IPS 0 to 2 | 8 (20) |
IPS ≥3 | 8 (20) |
First line treatment (n = 52)∗ | |
Chemotherapy | 49 (94) |
Radiotherapy | 20 (38) |
Immunotherapy | 1 (2) |
Time to first recurrence (N=60) | |
Median interval (range) (y) | 1.5 (0.4-13.6) |
cHL subtype (N = 60) | |
NSHL | 34 (57) |
MCHL | 22 (37) |
LRHL | 1 (2) |
cHL-NOS | 3 (5) |
EBV status (N = 60) | |
Negative | 47 (78) |
Positive | 13 (22) |
Total cohort (N = 60) . | n (%) . |
---|---|
Sex (N = 60) | |
Male | 37 (62) |
Female | 23 (38) |
Median age (N = 60) | 26 y (4-76 y) |
Pediatric (≤18 y) | 18 (30) |
Adults (>18 y) | 42 (70) |
Disease stage Ann Arbor (n = 52) | |
I | 6 (12) |
II | 19 (37) |
III | 17 (33) |
IV | 10 (19) |
Risk groups (n = 40) | |
Stages I to II (n = 24) | |
EORTC favorable | 9 (23) |
EORTC unfavorable | 15 (38) |
Stages III to IV (n = 16) | |
IPS 0 to 2 | 8 (20) |
IPS ≥3 | 8 (20) |
First line treatment (n = 52)∗ | |
Chemotherapy | 49 (94) |
Radiotherapy | 20 (38) |
Immunotherapy | 1 (2) |
Time to first recurrence (N=60) | |
Median interval (range) (y) | 1.5 (0.4-13.6) |
cHL subtype (N = 60) | |
NSHL | 34 (57) |
MCHL | 22 (37) |
LRHL | 1 (2) |
cHL-NOS | 3 (5) |
EBV status (N = 60) | |
Negative | 47 (78) |
Positive | 13 (22) |
EORTC, European Organization of Research and Treatment of Cancer; IPS, international prognostic score; LRHL, lymphocyte rich Hodgkin lymphoma; NOS, not otherwise specified.
If patients received combination therapy, multiple treatment categories were applicable, making the sum of all categories >100%. For detailed information, see supplemental Table 1.